Takeda Pharmaceuticals U.S.A.

Corporate brand

The U.S. commercial and pharmaceutical operating organization of Takeda Pharmaceutical Company Limited, supplying specialty medicines across gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Takeda Pharmaceuticals U.S.A. is the American operating organization of Takeda Pharmaceutical Company Limited, one of Japan’s major research-based biopharmaceutical companies. It is not an independent consumer brand or a health-information-technology company; its role is to develop, register, commercialize, and support Takeda medicines in the United States. The organization’s activities span specialty medicines, patient and healthcare-professional support, medical affairs, regulatory work, market access, pharmacovigilance, and commercial operations. Takeda’s U.S. business became substantially more important as the group shifted toward a focused biopharmaceutical model. The acquisition of Shire, completed in 2019, greatly expanded Takeda’s presence in the United States and added products and capabilities in gastroenterology, neuroscience, rare diseases, immunology, and plasma-derived therapies. The transaction also increased Takeda’s debt and led to a period of portfolio prioritization, asset divestitures, and cost-management efforts. In the United States, the resulting organization has been associated with several of Takeda’s largest and most visible specialty-medicine franchises. Important products marketed by Takeda in the American market have included Entyvio for inflammatory bowel disease, Iclusig for certain leukemias, Ninlaro for multiple myeloma, Trintellix for major depressive disorder, and therapies inherited or developed through the Shire combination, including Vyvanse for attention-deficit/hyperactivity disorder and binge-eating disorder. Product ownership, commercialization rights, indications, and availability can change over time, particularly where patents expire, generic competition begins, or Takeda transfers a product to another company. The U.S. organization also supports medicines in areas such as rare diseases and gastrointestinal disorders, consistent with Takeda’s global strategic priorities. Takeda Pharmaceuticals U.S.A. operates within the governance, compliance, and scientific framework of its Japanese parent rather than as a separately listed corporation. Takeda’s U.S. headquarters are in Lexington, Massachusetts, a major center for the company’s American commercial and corporate activities. The organization’s positioning is that of a science-led specialty biopharmaceutical company serving patients with complex, chronic, or serious conditions, rather than a broad primary-care or mass-market pharmaceutical supplier. The company’s U.S. operations are shaped by Food and Drug Administration regulation, reimbursement policy, patent and exclusivity rules, controlled-substance requirements for certain products, and scrutiny of pharmaceutical pricing and promotion. Its public-facing work includes disease education, patient assistance and support programs, clinical research, safety reporting, and engagement with physicians, hospitals, advocacy groups, and payers. Because Takeda Pharmaceuticals U.S.A. is a country organization within a multinational group, financial reporting is generally presented at Takeda group or segment level rather than as a separately reported U.S. brand.

History

Takeda Pharmaceuticals U.S.A. is the American operating organization of Takeda Pharmaceutical Company Limited. Its corporate history is therefore closely connected with the broader development of Takeda, whose origins trace to an Osaka medicine business established in 1781. The U.S. organization itself is not generally presented as an independently founded pharmaceutical company with a separate public listing; it functions as part of Takeda’s international structure. Takeda expanded its international research and commercial activities over many decades, building a U.S. presence around prescription medicines, clinical development, regulatory affairs, and commercial operations. The company’s American activities became particularly significant in specialty pharmaceutical fields, including gastrointestinal disease, oncology, neuroscience, and rare diseases. This focus reflected a broader move away from a diversified traditional pharmaceutical portfolio toward a smaller number of therapeutic areas where Takeda could support specialized research, clinical development, and patient services. A major turning point was Takeda’s acquisition of Millennium Pharmaceuticals in 2008. Millennium brought important oncology capabilities and the multiple-myeloma medicine Velcade, strengthening Takeda’s presence in the United States and in cancer research. Takeda later acquired the oncology company Ariad Pharmaceuticals in 2017, adding Iclusig and further expanding its hematology and oncology platform. The largest recent transformation came through the acquisition of Shire, announced in 2018 and completed in 2019. Shire contributed a substantial portfolio in rare diseases, neuroscience, gastroenterology, and plasma-derived therapies, as well as a broad U.S. infrastructure. The deal made Takeda one of the world’s largest specialty biopharmaceutical companies, but it also created significant financial leverage. Takeda subsequently pursued debt reduction, portfolio prioritization, and selected divestitures. These actions affected the composition of the products and businesses associated with its U.S. organization. In the American market, Takeda has commercialized or supported medicines including Entyvio, a biologic used in inflammatory bowel disease; Iclusig, a targeted oncology medicine; Ninlaro, an oral proteasome inhibitor for multiple myeloma; Trintellix, an antidepressant; and Vyvanse, a medicine for ADHD and binge-eating disorder that came through the Shire portfolio. The status of individual medicines is subject to regulatory decisions, patent expiry, generic entry, licensing arrangements, and business transfers. Takeda has also maintained U.S. research, medical-affairs, patient-support, and safety-monitoring activities across its priority therapeutic areas. Takeda Pharmaceuticals U.S.A. is governed as part of the Takeda group and is not a separately listed public company. Its headquarters in Lexington, Massachusetts, place it within the major U.S. biotechnology and pharmaceutical corridor around Boston. The organization’s current identity is that of a U.S. specialty-biopharmaceutical business: it supplies and supports prescription medicines for serious and chronic conditions, while operating under FDA requirements and the commercial, reimbursement, compliance, and pharmacovigilance standards applicable to the American pharmaceutical market.

2026
Takeda settles Trintellix False Claims allegations
[8]U.S. Department of Justice Trintellix Settlement Announcementjustice.gov
The Department of Justice announces a $13.6 million civil settlement concerning allegations of improper payments to healthcare professionals in connection with Trintellix prescriptions.
2025
Rhonda Pacheco becomes U.S. business president
[13]Rhonda Pacheco becomes U.S. business presidenttakeda.com
Rhonda Pacheco succeeds Julie Kim as president of Takeda’s U.S. Business Unit.
2024
Subcutaneous Entyvio receives U.S. Crohn’s disease approval
[12]Subcutaneous Entyvio receives U.S. Crohn’s disease approvaltakeda.com
The FDA approves subcutaneous maintenance administration of Entyvio for adults with moderately to severely active Crohn’s disease.
2020
COVID-19 patient assistance is expanded
[11]COVID-19 patient assistance is expandedtakeda.com
Takeda expands U.S. assistance for patients experiencing insurance loss or financial hardship during the COVID-19 crisis.
2019
Takeda completes the acquisition of Shire
[5]Takeda Completes Acquisition of Shiretakeda.com
The acquisition expands Takeda’s U.S. rare-disease, neuroscience, immunology, hematology, gastroenterology, and plasma-derived-therapy portfolio.
2019
NATPARA is recalled in the United States
[7]FDA NATPARA Recall Noticefda.gov
Takeda recalls all U.S. doses of NATPARA because of the potential presence of rubber particulate.
2014
Shire resolves U.S. marketing investigation
[10]Shire resolves U.S. marketing investigationtakeda.com
Shire reaches a $56.5 million agreement with U.S. authorities concerning historical sales and marketing practices involving several products later owned by Takeda.
2008
TAP Pharmaceuticals is integrated
[4]Takeda Corporate Historytakeda.com
Takeda integrates TAP after dividing the joint venture’s assets and operations with Abbott Laboratories.
2008
Millennium Pharmaceuticals is acquired
[9]Takeda enters the United Statestakeda.com
Takeda acquires Millennium Pharmaceuticals, strengthening its U.S. oncology research and commercial platform.
2005
Syrrx is integrated into Takeda’s research network
[4]Takeda Corporate Historytakeda.com
Takeda integrates Syrrx, expanding its U.S. structural-biology and drug-discovery capabilities.
1999
Actos launches in the United States
[4]Takeda Corporate Historytakeda.com
Takeda launches pioglitazone-based Actos in the United States and Japan.
1998
Takeda Pharmaceuticals America is established
[4]Takeda Corporate Historytakeda.com
Takeda establishes the wholly owned U.S. pharmaceutical marketing company now known as Takeda Pharmaceuticals U.S.A.
1997
Takeda America Holdings is established
[4]Takeda Corporate Historytakeda.com
Takeda establishes a U.S. holding structure for its American pharmaceutical business.
1985
Lupron is launched in the United States
[4]Takeda Corporate Historytakeda.com
TAP begins marketing Lupron, creating an important foundation for Takeda’s later U.S. specialty-pharmaceutical business.
1977
TAP Pharmaceuticals joint venture is formed
[9]Takeda enters the United Statestakeda.com
Takeda and Abbott Laboratories establish Takeda-Abbott Products Pharmaceuticals, later known as TAP Pharmaceuticals.
1967
Takeda enters the United States
[9]Takeda enters the United Statestakeda.com
Takeda establishes a U.S. corporate presence in New York to import vitamins and market nucleotides.

Products and positioning

U.S. specialty-biopharmaceutical operating organization focused on innovative and life-transforming medicines for gastrointestinal and inflammatory diseases, rare diseases, plasma-derived conditions, oncology, neuroscience, vaccines, and selected hematologic disorders. The organization emphasizes patient access, scientific innovation, specialty-care partnerships, and integrated commercial, research, manufacturing, and support capabilities.

Gastroenterology
Entyvio
Entyvio, or vedolizumab, is a biologic medicine used in the United States for adults with moderately to severely active ulcerative colitis and Crohn’s disease. It is a central Takeda gastroenterology franchise and is available through intravenous administration and, for maintenance treatment, a subcutaneous pen. Takeda supports eligible U.S. patients through EntyvioConnect, which provides nurse education, injection-training resources, insurance navigation, and financial-support information.
Rare diseases · 2018
Takhzyro
Takhzyro, or lanadelumab, is a long-term preventive treatment for hereditary angioedema. It entered Takeda’s U.S. portfolio through the Shire acquisition and illustrates the company’s emphasis on specialty medicines for rare conditions. The product is administered by injection and is supported by Takeda’s patient-service infrastructure, specialty-pharmacy relationships, and disease-education activities.
Neuroscience · 2007
Vyvanse
Vyvanse, or lisdexamfetamine dimesylate, is a prescription stimulant marketed in the United States for attention-deficit/hyperactivity disorder and binge-eating disorder in specified patient populations. The product was inherited from Shire in 2019 and became one of Takeda’s most recognizable U.S. neuroscience brands. Its controlled-substance status means that commercialization is subject to extensive prescribing, distribution, and regulatory requirements.
Neuroscience · 2013
Trintellix
Trintellix, or vortioxetine, is an antidepressant approved in the United States for the treatment of major depressive disorder in adults. Takeda markets the product through its neuroscience organization and has supported research concerning cognition and processing speed in depression. In 2026, Takeda Pharmaceuticals U.S.A. agreed to a civil settlement concerning government allegations about improper promotional payments related to Trintellix prescribing; the settlement did not constitute an admission or determination of liability.
Oncology · 2015
Ninlaro
Ninlaro, or ixazomib, is an oral proteasome inhibitor used in combination regimens for multiple myeloma in appropriate patients. It is part of Takeda’s oncology portfolio and reflects the company’s strategy of developing medicines that can be incorporated into outpatient treatment pathways. The product is commercialized alongside other Takeda oncology brands and research programs focused on hematologic malignancies.
Oncology · 2012
Iclusig
Iclusig, or ponatinib, is a targeted oncology medicine used for selected forms of Philadelphia chromosome-positive leukemia, including chronic myeloid leukemia and acute lymphoblastic leukemia. It became part of Takeda’s portfolio through the acquisition of ARIAD Pharmaceuticals. The medicine is managed within Takeda’s hematology and oncology business and is supported by specialized prescribing, safety-monitoring, and patient-access programs.
Plasma-derived and recombinant therapies
Advate and Adynovate
Advate and Adynovate are recombinant factor VIII therapies used in the management of hemophilia A. The products entered Takeda’s U.S. portfolio through the Shire acquisition and are part of the company’s broader rare-disease and plasma-derived-therapies platform. Their commercialization involves specialty distribution, treatment education, home-infusion considerations, and close coordination with hematologists and hemophilia treatment centers.
Plasma-derived therapies
Gammagard
Gammagard products are immunoglobulin therapies used in selected primary immunodeficiency and neurological indications. They are part of Takeda’s plasma-derived-therapies business, which depends on plasma collection, fractionation, manufacturing quality systems, specialty distribution, and ongoing patient support. The U.S. portfolio includes intravenous and subcutaneous immunoglobulin-related offerings and serves patients requiring long-term replacement or immune-modulating therapy.

Controversies

2026
Trintellix promotional-payment allegations
The U.S. Department of Justice announced a $13,670,921 civil settlement with Takeda Pharmaceuticals U.S.A. concerning allegations that speaker honoraria and meals were provided to healthcare professionals to induce Trintellix prescriptions. The government stated that the claims resolved by the settlement were allegations and that there had been no determination of liability.
Source
2014
Shire U.S. marketing-practices settlement
Before its acquisition by Takeda, Shire agreed to pay $56.5 million to resolve a U.S. government investigation concerning historical sales and marketing practices involving Adderall XR, Vyvanse, Daytrana, Lialda, and Pentasa. Shire also agreed to a separate Louisiana-related payment and a corporate integrity agreement. The matter is relevant to Takeda’s U.S. history because the affected businesses and products became part of Takeda in 2019.
Source

2020Expanded COVID-19 Patient Assistance
United States
Takeda expanded patient-assistance measures during the COVID-19 crisis for eligible patients affected by loss of insurance or financial hardship. The initiative extended the company’s access strategy beyond medicine promotion by addressing affordability and continuity-of-treatment concerns during a public-health emergency.
Outcome. Takeda continued to direct eligible patients toward product-specific assistance and support programs.
Source
2020EntyvioConnect Patient Support
United States
EntyvioConnect provides one-on-one nurse education, treatment-navigation resources, injection training, medication reminders, and eligible financial-support information for patients prescribed Entyvio.
Outcome. The program remains part of Takeda’s U.S. patient-support infrastructure.
Source
2015Takeda Cares Day
United States
Takeda employees participated in an annual U.S. community-service and philanthropy program supporting nonprofit organizations in health, science education, and community vitality.
Outcome. The program expanded beyond the Chicago area and became a visible component of Takeda’s U.S. community-engagement activities.
Source

Brand decisions

2025
Appoint Rhonda Pacheco to lead the U.S. Business Unitleadership_change
Background
Julie Kim was selected to succeed Christophe Weber as Takeda’s global president and chief executive officer in June 2026.
Action taken
Takeda appointed Rhonda Pacheco as president of the U.S. Business Unit and U.S. country head, effective September 29, 2025.
Aftermath
Pacheco assumed responsibility for Takeda’s largest national market and joined the company’s Executive Team.
Source
2024
Expand Entyvio to subcutaneous maintenance treatmentProduct launch
Background
Takeda sought to provide patients with inflammatory bowel disease an alternative to intravenous maintenance administration.
Action taken
The FDA approved subcutaneous Entyvio maintenance treatment for adults with moderately to severely active Crohn’s disease, following an earlier ulcerative-colitis approval.
Aftermath
Entyvio became available in the United States in both intravenous and subcutaneous maintenance formats for the relevant indications.
Source
2019
Complete the acquisition of ShireM&A
Background
Takeda sought to expand its geographic reach, specialty-medicine portfolio, and research pipeline, with the United States representing one of the most important markets for the combined company.
Action taken
Takeda completed the acquisition of Shire on January 8, 2019, bringing major rare-disease, neuroscience, hematology, immunology, gastroenterology, and plasma-derived-therapy businesses into the group.
Aftermath
The transaction made the United States a central Takeda market and materially increased the scale of its U.S. commercial, research, manufacturing, and patient-support operations.
Combined annual revenue cited at transaction completion. More than USD 30 billion for the combined company (January 8, 2019 transaction announcement)
Source
2019
Recall NATPARA in the United StatesOther
Background
Takeda identified a potential risk that rubber particulate could be present in NATPARA products.
Action taken
Takeda issued a U.S. recall covering all doses of NATPARA and notified patients and prescribers about the potential safety implications of abrupt discontinuation.
Aftermath
The recall was later recorded by the FDA as completed and terminated. Takeda subsequently pursued regulatory steps to address the manufacturing issue, but commercial return remained delayed after a 2022 Complete Response Letter.
Source
2008
Integrate TAP Pharmaceuticals and build an independent U.S. platformStrategy
Background
Takeda and Abbott agreed to divide the TAP joint venture’s business after more than two decades of collaboration in the United States.
Action taken
Takeda integrated TAP into its U.S. organization and retained important development, commercialization, and portfolio capabilities.
Aftermath
The decision strengthened Takeda’s direct U.S. operating model and created a platform for later expansion through oncology and specialty-pharmaceutical acquisitions.
Source

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/takeda-pharmaceuticals-usa · Editorial policy · How profiles are compiled